Inclisiran Tx Dramatically Cuts LDL in Pooled Analysis

]]>(MedPage Today) -- Treatment with inclisiran, an investigational agent targeting PCSK9 via small interfering RNA, reduced LDL cholesterol by more than half in patients with atherosclerotic cardiovascular disease (ASCVD), according to pooled analysis...